Streetbeat News

Price Targets

ACAD

Mizuho analyst Uy Ear has maintained a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and increased the price target from $35 to $40, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 12:05 pm

NTRA

Over the past three months, 8 analysts have provided diverse ratings for Natera (NASDAQ:NTRA), ranging from bullish to bearish. The recent ratings show a majority of bullish opinions, with 5 bullish and 3 somewhat bullish ratings. The 12-month price targets have an average of $68.62, with a high of $87.00 and a low of $52.00, marking a 2.9% decrease from the previous average. Analysts from firms like Goldman Sachs, Guggenheim, TD Cowen, Raymond James, Morgan Stanley, UBS, and Piper Sandler have adjusted their ratings and price targets, reflecting their latest views on Natera's market performance. Natera's financial performance shows a revenue growth of 27.38%, a high net margin of -40.64%, a below-average ROE of -15.79%, and a low ROA of -8.09%. The company has a debt-to-equity ratio of 0.56, indicating less reliance on debt financing.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 12:00 pm

BSX

Wells Fargo analyst Larry Biegelsen has reiterated an Overweight rating on Boston Scientific (NYSE:BSX) and maintained a price target of $62.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 11:51 am

OTLK

Ascendiant Capital analyst Edward Woo has reaffirmed a Buy rating on Outlook Therapeutics (NASDAQ:OTLK) and increased the price target from $1.5 to $2.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 11:47 am

CODX

HC Wainwright & Co. analyst Yi Chen has reiterated a Neutral rating on Co-Diagnostics (NASDAQ:CODX) and maintained a price target of $3. The reaffirmation of the Neutral stance and price target suggests that the analyst sees the stock performing in line with market expectations without significant upside or downside risks in the near term.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 11:34 am

BKNG

Ascendiant Capital analyst Edward Woo has reaffirmed a Buy rating on Booking Holdings (NASDAQ:BKNG) and increased the price target from $3700 to $3900.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 11:31 am

EXPE

Ascendiant Capital analyst Edward Woo has reaffirmed a Buy rating on Expedia Group (NASDAQ:EXPE) and increased the price target from $133 to $168.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 11:29 am

KSCP

Ascendiant Capital analyst Edward Woo has maintained a Buy rating on Knightscope (NASDAQ:KSCP) and increased the price target from $3.75 to $4, as reported on December 28, 2023.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 11:24 am

TRIP

Ascendiant Capital analyst Edward Woo has maintained a Buy rating on TripAdvisor (NASDAQ:TRIP) and increased the price target from $27 to $30, as reported on December 28, 2023.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 11:20 am

NTRA

Goldman Sachs analyst Matthew Sykes has reaffirmed a Buy rating on Natera (NASDAQ:NTRA) and increased the price target from $56 to $64.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 11:12 am